FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods.

Ginkgo Bioworks Holdings, Inc. (DNA) has been on a downward spiral lately with significant selling pressure. After declining ...

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a ...

Ginkgo Bioworks (DNA) announced a new contract with the Advanced Research Projects Agency for Health, or ARPA-H, alongside partners Tritica ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...

Reshma Shetty co-founded Ginkgo Bioworks in 2008, a leading organism design company. As President and COO, she has overseen ...

Shares of Ginkgo Bioworks Holdings, Inc. (DNA) have gained 2% over the past four weeks to close the last trading session at $6.78, but there could still be a solid upside left in the stock if ...

Ginkgo Bioworks gains a $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems.

Ginkgo Bioworks (DNA) is down -4.8%, or -27c to $5.39.Don't Miss Our End of Quarter Offers: Discover the latest stocks recommended by top Wall ...

The average of price targets set by Wall Street analysts indicates a potential upside of 41.6% in Ginkgo Bioworks (DNA). While the effectiveness of this highly sought-after metric is questionable, the ...

Ginkgo Bioworks and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems Under the $29 million ...